Amgen Talks Dual Pricing Strategy For Amjevita
Debut US Humira Biosimilar Has Been Priced To Address ‘Complexity Of The US Market’
In the wake of Amgen announcing a dual pricing strategy for its debut US adalimumab biosimilar – with the firm’s newly-launched Amjevita version being offered at both 5% off and 55% off the WAC of the Humira original – investors and analysts were keen to press the firm for further details of its pricing strategy.
